[gyrA基因的突变和parC fluoroquinolone-resistant大肠杆菌分离株的基因零星的腹泻病例)。

文章的细节

引用

复制到剪贴板

石黑浩F,东邦M,山崎M, Matsuyuki年代,守屋K,田中D, Isobe J,清田Y, Muraoka M

[gyrA基因的突变和parC fluoroquinolone-resistant大肠杆菌分离株的基因零星的腹泻病例)。

Kansenshogaku Zasshi。2006年9月,80(5):507 - 12所示。

PubMed ID

17073264 (在PubMed

]

文摘

我们研究107年分离的大肠杆菌O153零星的腹泻病例在福井,富山,爱知,和传奇县从1991年到2005年对抗菌药物敏感性和氟喹诺酮类耐药性的机制,根据标准磁盘扩散。12药物测试,氨苄青霉素抗性分离株的72.9%,显示48.6%链霉素、四环素至46.7%,sulfisoxazole至46.7%,甲氧苄氨嘧啶/磺胺甲恶唑29.9%,萘啶酸(钠)为29.9%,和环丙沙星(CPFX) 24.3%。十32隔离药物抵抗3 - 6 18和16个分离株耐7 - 10对NA和CPFX药物的抵抗力。氨基酸的突变喹诺酮gyrA resistance-determining地区和帕洛阿尔托研究中心在24分离株耐药基因检测NA和CPFX和1分离耐NA。前拥有的组合双替换(GyrA S83L和D87L)和一个替换在帕洛阿尔托研究中心(S80I)。大约24隔离拥有另一个单替换(E84V或E84G A108T)在帕洛阿尔托研究中心。25隔离被分为4个类型如下。1分离类型1:GyrA (S83L)和帕洛阿尔托研究中心(S80I);12隔离2型:GyrA (S83L和D87N)和帕洛阿尔托研究中心(S80I);8隔离型3:GyrA (S83L和D87N)和帕洛阿尔托研究中心(S80I和E84G / S80R和E84V); and 4 isolate as type 4: GyrA (S83L and D87N) and ParC (S80I and A108T). In the relationship between amino acid mutations and minimal inhibitory concentrations (MIC) of fluoroquinolone, MICs of CPFX, ofloxacin, and norfloxacin showed 1microg/mL, 2microg/mL and 8microg/mL in type 1; 8 approximately 32microg/mL, 8 approximately 32microg/mL and 16 approximately 256microg/mL in type 2; and 32 approximately 256microg/mL' 32 approximately 128microg/mL and 128-->512microg/ mL in types 3 and 4. These results suggest that most of multiple-antimicrobial-resitant E. coli O153 isolates from sporadic diarrhea cases were resistant to fluoroquinolones and possessed mutations at gyrA and parC genes associated with fluoroquinolone resistance.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
氧氟沙星	DNA拓扑异构酶4单元	蛋白质	流感嗜血杆菌(写明ATCC 51907株/ DSM 11121 / KW20 / Rd)	是的	抑制剂	细节